Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Gene expression profiles reveal homeostatic dynamics during interferon-beta therapy in multiple sclerosis.

Annibali V, Di Giovanni S, Cannoni S, Giugni E, Bomprezzi R, Mattei C, Elkahloun A, Coccia EM, Alfò M, Orzi F, Ristori G, Salvetti M.

Autoimmunity. 2007 Feb;40(1):16-22.

PMID:
17364493
2.

Interferon-beta therapy in multiple sclerosis: the short-term and long-term effects on the patients' individual gene expression in peripheral blood.

Hecker M, Hartmann C, Kandulski O, Paap BK, Koczan D, Thiesen HJ, Zettl UK.

Mol Neurobiol. 2013 Dec;48(3):737-56. doi: 10.1007/s12035-013-8463-1. Epub 2013 May 1.

PMID:
23636981
3.

Network analysis of transcriptional regulation in response to intramuscular interferon-β-1a multiple sclerosis treatment.

Hecker M, Goertsches RH, Fatum C, Koczan D, Thiesen HJ, Guthke R, Zettl UK.

Pharmacogenomics J. 2012 Apr;12(2):134-46. doi: 10.1038/tpj.2010.77. Epub 2010 Oct 19. Erratum in: Pharmacogenomics J. 2012 Aug;12(4):360.

PMID:
20956993
4.

Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients.

Weinstock-Guttman B, Bhasi K, Badgett D, Tamaño-Blanco M, Minhas M, Feichter J, Patrick K, Munschauer F, Bakshi R, Ramanathan M.

J Neuroimmunol. 2008 Dec 15;205(1-2):113-25. doi: 10.1016/j.jneuroim.2008.09.004. Epub 2008 Oct 23.

PMID:
18950872
5.

Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1.

Feng X, Petraglia AL, Chen M, Byskosh PV, Boos MD, Reder AT.

J Neuroimmunol. 2002 Aug;129(1-2):205-15.

PMID:
12161037
6.

Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis.

Hong J, Zang YC, Hutton G, Rivera VM, Zhang JZ.

J Neuroimmunol. 2004 Jul;152(1-2):126-39.

PMID:
15223245
7.

Regulatory effects of interferon-β on osteopontin and interleukin-17 expression in multiple sclerosis.

Hong J, Hutton GJ.

J Interferon Cytokine Res. 2010 Oct;30(10):751-7. doi: 10.1089/jir.2010.0082. Review.

PMID:
20874252
8.

Quantitative differences in the immunomodulatory effects of Rebif and Avonex in IFN-β 1a treated multiple sclerosis patients.

Christophi GP, Christophi JA, Gruber RC, Mihai C, Mejico LJ, Massa PT, Jubelt B.

J Neurol Sci. 2011 Aug 15;307(1-2):41-5. doi: 10.1016/j.jns.2011.05.024. Epub 2011 Jun 11.

9.

Disease protection and interleukin-10 induction by endogenous interferon-β in multiple sclerosis?

Hesse D, Krakauer M, Lund H, Søndergaard HB, Limborg SJ, Sørensen PS, Sellebjerg F.

Eur J Neurol. 2011 Feb;18(2):266-72. doi: 10.1111/j.1468-1331.2010.03116.x.

PMID:
20561040
10.

IFN-β Therapy Regulates TLR7-Mediated Response in Plasmacytoid Dendritic Cells of Multiple Sclerosis Patients Influencing an Anti-Inflammatory Status.

Severa M, Rizzo F, Giacomini E, Annibali V, Gafa V, Romano S, Buscarinu MC, Fornasiero A, Salvetti M, Coccia EM.

J Interferon Cytokine Res. 2015 Sep;35(9):668-81. doi: 10.1089/jir.2014.0207. Epub 2015 Apr 29.

PMID:
25923141
11.

Small non-coding RNA signature in multiple sclerosis patients after treatment with interferon-β.

De Felice B, Mondola P, Sasso A, Orefice G, Bresciamorra V, Vacca G, Biffali E, Borra M, Pannone R.

BMC Med Genomics. 2014 May 17;7:26. doi: 10.1186/1755-8794-7-26.

12.

Interferon β-1a reduces increased interleukin-16 levels in multiple sclerosis patients.

Nischwitz S, Faber H, Sämann PG, Domingues HS, Krishnamoorthy G, Knop M, Müller-Sarnowski F, Yassouridis A, Weber F.

Acta Neurol Scand. 2014 Jul;130(1):46-52. doi: 10.1111/ane.12215. Epub 2014 Jan 25.

PMID:
24571587
13.

Interferon-β inhibits toll-like receptor 9 processing in multiple sclerosis.

Balashov KE, Aung LL, Vaknin-Dembinsky A, Dhib-Jalbut S, Weiner HL.

Ann Neurol. 2010 Dec;68(6):899-906. doi: 10.1002/ana.22136.

14.

Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy.

Singh MK, Scott TF, LaFramboise WA, Hu FZ, Post JC, Ehrlich GD.

J Neurol Sci. 2007 Jul 15;258(1-2):52-9. Epub 2007 Apr 30.

PMID:
17467740
15.

Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis.

Stürzebecher S, Wandinger KP, Rosenwald A, Sathyamoorthy M, Tzou A, Mattar P, Frank JA, Staudt L, Martin R, McFarland HF.

Brain. 2003 Jun;126(Pt 6):1419-29.

PMID:
12764062
16.

Gene expression profiling of the response to interferon beta in Epstein-Barr-transformed and primary B cells of patients with multiple sclerosis.

Khsheibun R, Paperna T, Volkowich A, Lejbkowicz I, Avidan N, Miller A.

PLoS One. 2014 Jul 15;9(7):e102331. doi: 10.1371/journal.pone.0102331. eCollection 2014.

17.

Cellular immune responses in multiple sclerosis patients treated with interferon-beta.

Bustamante MF, Rio J, Castro Z, Sánchez A, Montalban X, Comabella M.

Clin Exp Immunol. 2013 Mar;171(3):243-6. doi: 10.1111/cei.12016.

18.

Multiple sclerosis: levels of interleukin-10-secreting blood mononuclear cells are low in untreated patients but augmented during interferon-beta-1b treatment.

Ozenci V, Kouwenhoven M, Huang YM, Xiao B, Kivisäkk P, Fredrikson S, Link H.

Scand J Immunol. 1999 May;49(5):554-61.

19.

Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation.

Sellebjerg F, Krakauer M, Hesse D, Ryder LP, Alsing I, Jensen PE, Koch-Henriksen N, Svejgaard A, Soelberg Sørensen P.

Eur J Neurol. 2009 Dec;16(12):1291-8. doi: 10.1111/j.1468-1331.2009.02716.x. Epub 2009 Jun 22.

PMID:
19558503
20.

[Interferon -beta therapy in multiple sclerosis].

Satoh J.

Nihon Rinsho. 2006 Jul;64(7):1297-309. Review. Japanese.

PMID:
16838648

Supplemental Content

Support Center